PNP as a Metabolic and Prognostic Driver of Breast Cancer Aggressiveness: Insights from Patient Tissue and Cell Models
Collectively, PNP emerges as a promising biomarker of BC aggressiveness and progression. Its reciprocal interaction with HER-2 underscores its potential as a therapeutic target. Dual targeting of PNP and HER-2 may offer a novel strategy for improving outcomes in aggressive BC subtypes.
Authors
- Noura Alkhayyal
- Riyad Bendardaf (ORCID: https://orcid.org/0000-0002-5158-4590)
- Sarra B. Shakartalla
- Zainab Al Shareef (ORCID: https://orcid.org/0000-0003-4213-1052)
- Nival Ali
- Shahenaz S. Salih
- Sameh S. M. Soliman (ORCID: https://orcid.org/0000-0002-7691-615X)
- Iman M. Talaat (ORCID: https://orcid.org/0000-0003-1180-0778)
Institutions
- University of Sharjah (AE)
- Alexandria University (EG)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-12-01
- DOI
- https://doi.org/10.32604/or.2025.070808
- Primary Topic
- Cancer, Stress, Anesthesia, and Immune Response
- Type
- article
- Field-Weighted Citation Impact
- 0.00